Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.56 |
| ▸ | CNR1 | P21554 | 5/20 | 0.48 |
| ▸ | PHGDH | O43175 | 4/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.36 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14299985 | 0.89 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL12827538 | 0.85 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL1465546 | 0.84 | CNR2 (0.78) | CNR2CNR1PHGDHMAPT | |
| SCHEMBL12827709 | 0.82 | CNR2 (0.46) | CNR2CNR1ABCC9ABCC8KCNJ11 | |
| SCHEMBL14299743 | 0.81 | CNR2 (0.53) | CNR2CNR1MAPT | |
| SCHEMBL13062811 | 0.76 | CNR2 (0.41) | CNR2MAPT | |
| SCHEMBL775447 | 0.76 | CNR2 (0.48) | CNR2CNR1PHGDHMAPT | |
| SCHEMBL3969896 | 0.75 | CNR2 (0.61) | CNR2CNR1PHGDHMAPT | |
| SCHEMBL1463951 | 0.74 | CNR2 (0.67) | CNR2CNR1ABCC9ABCC8KCNJ11 | |
| SCHEMBL1464598 | 0.74 | CNR2 (0.78) | CNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329735-B2 | Tetrazole compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120071529-A1 | Tetrazole Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071529-A1 | Tetrazole Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885PHGDH 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.